Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1965 2
1966 1
1967 1
1968 2
1969 1
1970 3
1971 3
1972 3
1973 1
1974 7
1975 21
1976 19
1977 22
1978 17
1979 30
1980 40
1981 41
1982 48
1983 49
1984 70
1985 42
1986 59
1987 64
1988 58
1989 74
1990 80
1991 95
1992 119
1993 111
1994 118
1995 125
1996 147
1997 173
1998 187
1999 171
2000 202
2001 210
2002 228
2003 243
2004 282
2005 263
2006 207
2007 179
2008 185
2009 208
2010 233
2011 252
2012 263
2013 232
2014 271
2015 233
2016 254
2017 264
2018 233
2019 218
2020 235
2021 243
2022 212
2023 180
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

6,915 results

Results by year

Filters applied: . Clear all
Page 1
Lobular Carcinoma In Situ.
Wen HY, Brogi E. Wen HY, et al. Surg Pathol Clin. 2018 Mar;11(1):123-145. doi: 10.1016/j.path.2017.09.009. Epub 2017 Dec 8. Surg Pathol Clin. 2018. PMID: 29413653 Free PMC article. Review.
Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasive carcinoma after classic LCIS diagnosis is approximately 9 to 10 times that of the general population. ...
Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasi …
Male Breast Carcinoma: A Clinical and Pathological Review.
Javidiparsijani S, Rosen LE, Gattuso P. Javidiparsijani S, et al. Int J Surg Pathol. 2017 May;25(3):200-205. doi: 10.1177/1066896916675953. Epub 2016 Nov 10. Int J Surg Pathol. 2017. PMID: 27831530 Review.
Because of its rarity, data regarding the etiology, risk factors, diagnosis, management, and prognosis of MBC are limited. MBC shares some similarities with female breast carcinoma (FBC). This review will address the important clinical, histopathological, immunohist …
Because of its rarity, data regarding the etiology, risk factors, diagnosis, management, and prognosis of MBC are limited. MBC shares some s …
Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies.
Drekolias D, Mamounas EP. Drekolias D, et al. Breast J. 2019 Nov;25(6):1192-1197. doi: 10.1111/tbj.13416. Epub 2019 Jun 27. Breast J. 2019. PMID: 31250492 Review.
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer consisting of various combinations of malignant epithelial and mesenchymal cells. ...
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer consisting of various combinations of malignant …
Neuroendocrine breast carcinoma: a rare but challenging entity.
Trevisi E, La Salvia A, Daniele L, Brizzi MP, De Rosa G, Scagliotti GV, Di Maio M. Trevisi E, et al. Med Oncol. 2020 Jul 25;37(8):70. doi: 10.1007/s12032-020-01396-4. Med Oncol. 2020. PMID: 32712767 Free PMC article. Review.
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2-5% of all invasive breast carcinomas. ...Due to its rarity and lack of random …
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast carcinoma (NEBC), incl …
Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma.
Abada E, Daaboul F, Ebare K, Jang H, Fehmi Z, Kim S, Ali-Fehmi R, Bandyopadhyay S. Abada E, et al. Arch Pathol Lab Med. 2022 Mar 1;146(3):341-350. doi: 10.5858/arpa.2020-0830-OA. Arch Pathol Lab Med. 2022. PMID: 34237136 Free article.
CONTEXT.-: Metaplastic breast carcinoma is an aggressive form of breast cancer that accounts for 0.5% to 3% of all breast cancers. ...CONCLUSIONS.-: A larger tumor size and distant metastatic disease are associated with worse overall survival in patients with metapl …
CONTEXT.-: Metaplastic breast carcinoma is an aggressive form of breast cancer that accounts for 0.5% to 3% of all breast canc …
Lobular carcinoma in situ: diagnostic criteria and molecular correlates.
Sokolova A, Lakhani SR. Sokolova A, et al. Mod Pathol. 2021 Jan;34(Suppl 1):8-14. doi: 10.1038/s41379-020-00689-3. Epub 2020 Oct 6. Mod Pathol. 2021. PMID: 33024303 Free article. Review.
Lobular neoplasia (LN) is an atypical proliferation of small, dyscohesive epithelial cells within the terminal duct lobular unit (TDLU), with or without pagetoid extension and encompasses both lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH). LN is a non-ob …
Lobular neoplasia (LN) is an atypical proliferation of small, dyscohesive epithelial cells within the terminal duct lobular unit (TDLU), wit …
Breast carcinoma: molecular profiling and updates.
Bandyopadhyay S, Ali-Fehmi R. Bandyopadhyay S, et al. Clin Lab Med. 2013 Dec;33(4):891-909. doi: 10.1016/j.cll.2013.08.009. Clin Lab Med. 2013. PMID: 24267194 Review.
Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A, Khan U, Rathod H, Jain K, Dwivedi A, Rajesh A. Buch A, et al. J Cancer Res Ther. 2023 Oct 1;19(7):1697-1713. doi: 10.4103/jcrt.jcrt_188_22. Epub 2023 Apr 25. J Cancer Res Ther. 2023. PMID: 38376268 Free article.
We aim to systematically review the existing literature and conduct a meta-analysis to assess the prognostic implication of tumor budding in breast carcinoma. A systematic search was performed to identify studies that compared different prognostic variables between …
We aim to systematically review the existing literature and conduct a meta-analysis to assess the prognostic implication of tumor budding in …
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP, Haberberger J, McGregor K, Mata DA, Decker B, Hiemenz MC, Lechpammer M, Danziger N, Schiavone K, Creeden J, Graf RP, Strowd R, Lesser GJ, Razis ED, Bartsch R, Giannoudis A, Bhogal T, Lin NU, Pusztai L, Ross JS, Palmieri C, Ramkissoon SH. Huang RSP, et al. Oncologist. 2021 Oct;26(10):835-844. doi: 10.1002/onco.13855. Epub 2021 Jun 23. Oncologist. 2021. PMID: 34105210 Free PMC article.
BACKGROUND: Among patients with breast carcinoma who have metastatic disease, 15%-30% will eventually develop brain metastases. We examined the genomic landscape of a large cohort of patients with breast carcinoma brain metastases (BCBMs) and compared …
BACKGROUND: Among patients with breast carcinoma who have metastatic disease, 15%-30% will eventually develop brain metastases …
6,915 results